Boston, United States
Kojin Therapeutics, founded in 2020, is pioneering a novel approach to developing transformative medicines targeting ferroptosis and cell-state biology. Based in Boston, Massachusetts, the company takes its inspiration from the Japanese deity known for taming fire, aligning with their mission of harnessing science for the greater good.
Kojin's drug-discovery platform uniquely integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to specifically modulate ferroptosis. This approach has vast potential in treating cancer, autoimmune, and inflammatory diseases. The team includes experts in chemical biology, genetics, immunology, cancer therapeutics, and biotech entrepreneurship.
In their most recent funding round, Kojin secured a $60.00M Series A investment on 09 June 2021 from notable investors such as Polaris Partners, Binney Street Capital, Leaps by Bayer, Newpath Partners, Cathay Capital, Eventide Asset Management, AbbVie, and Alexandria, highlighting confidence in Kojin's innovative approaches and experienced team. The company operates at the forefront of Biopharma and Life Sciences, with significant promise in the healthcare sector.
